Rasagiline |
Antidepressant |
MAO-A and MAO-B in the brain ↓ |
[86] |
|
Methamphetamine (METH) |
Addiction |
Expression of fosb, fra1, and fra2 in the nucleus accumbens (NAc) ↓ |
[87] |
|
Ladostigil |
Antidepressant |
MAO-A and MAO-B in the brain ↓ |
[86] |
|
Risperidone/donepezil |
Parkinsonian features |
Dopamine transporter activity ↑ |
[88] |
|
Cocaine, heroin, or methamphetamine |
Addiction |
Extracellular dopamine in CNS ↑ |
[89] |
|
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) |
Parkinsonian features |
Dopamine and TH ↓ |
[90] |
|
PAOPA |
Schizophrenia |
Active site of the dopamine D(2) receptor ↓ |
[91] |
|
Methylphenidate |
Cocaine addiction |
Dopamine transporter ↓ |
[92] |
|
Phenelzine |
Depression and anxiety disorders |
Dopamine levels in brain ↑ |
[93] |
|
Amphetamine |
Attention deficit hyperactivity disorder |
Extracellular dopamine ↑ |
[94] |
|
L-DOPA |
Parkinson disease |
Brain dopamine levels ↑ |
[95] |
|
3,4-Methylenedioxymethamphetamine |
Addiction |
Brain dopamine levels ↑ |
[96] |
|
Flupenthixol, perphenazine, and zotepine |
Tauopathies |
Dopamine D(2) receptor ↓ |
[97] |
|
Asenapine |
Acute schizophrenia, manic episodes, bipolar I disorder |
Brain dopamine levels ↑ |
[98] |
|
Pramipexole |
Depression |
Dopamine receptor D(3) ↑ |
[99] |